An Ohio State hematologist discusses a new trial comparing tovorafenib plus rituximab with standard cladribine-based treatment, and what quality of life means for patients.
Seema Bhat
Advertisement
Articles by Seema Bhat
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
Patient Advocacy Advice From a Colon Cancer Survivor
2
Medicare Part D 2027: What a $2,400 Cap Means for Cancer Drugs
3
Living With BRCA and Ovarian Cancer: Leanne Citrone's Story
4
Inside the Clinic: How One Hematologist Approaches a Rare Leukemia
5